➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Johnson and Johnson
Moodys
Express Scripts

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

ARRANON Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Arranon patents expire, and when can generic versions of Arranon launch?

Arranon is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in ARRANON is nelarabine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelarabine profile page.

Drug patent expirations by year for ARRANON
Drug Prices for ARRANON

See drug prices for ARRANON

Recent Clinical Trials for ARRANON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 1/Phase 2
National Cancer Institute (NCI)Phase 1/Phase 2
Washington University School of MedicinePhase 2

See all ARRANON clinical trials

Pharmacology for ARRANON

US Patents and Regulatory Information for ARRANON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ARRANON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for ARRANON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0294114 300302 Netherlands   Start Trial 300302, 20080527, EXPIRES: 20130526
0294114 C300302 Netherlands   Start Trial PRODUCT NAME: NELARABINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR BAAR ZOUT, ETHER OF ESTER; REGISTRATION NO/DATE: EU/1/07/403/001 20070822
0294114 SPC/GB08/006 United Kingdom   Start Trial PRODUCT NAME: NELARABINE, OR ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ETHERS, ESTERS, OR SALTS OF SUCH ESTERS THEREOF.; REGISTERED: UK EU/1/07/403/001 20070822
0294114 C00294114/01 Switzerland   Start Trial PRODUCT NAME: NELARABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57899 08.08.2007
0294114 55/2007 Austria   Start Trial PRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070822
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Johnson and Johnson
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.